human
bovin
respiratori
syncyti
virus
hrsv
brsv
two
close
relat
worldwid
preval
virus
lead
caus
sever
airway
diseas
children
calv
respect
efficaci
commerci
bovin
vaccin
need
improv
human
vaccin
licens
yet
report
nasal
vaccin
hrsv
nucleoprotein
produc
recombin
ringshap
nanoparticl
n
sr
protect
mice
viral
challeng
hrsv
aim
work
evalu
new
vaccin
use
conserv
viral
antigen
calv
natur
host
brsv
calv
free
colostr
natur
antibrsv
antibodi
vaccin
n
sr
either
intramuscularli
intramuscularli
intranas
use
montanid
tm
adjuv
challeng
brsv
vaccin
calv
develop
antin
antibodi
blood
nasal
secret
nspecif
cellular
immun
local
lymph
node
clinic
monitor
postchalleng
demonstr
moder
respiratori
patholog
local
lung
tissu
consolid
nonvaccin
calv
significantli
reduc
vaccin
calv
vaccin
calv
lower
viral
load
nonvaccin
control
calv
thu
n
sr
vaccin
calv
provid
crossprotect
immun
brsv
infect
without
advers
inflammatori
reaction
riffault
contribut
equal
work
epizoot
respiratori
diseas
observ
dairi
herd
beef
herd
mortal
caus
brsv
infect
rang
gener
reach
outbreak
control
brsv
infect
high
prioriti
anim
health
farm
organ
econom
reason
also
due
impact
anim
welfar
sever
commerci
brsv
vaccin
includ
modifiedl
viru
inactiv
singl
fraction
avail
use
cattl
efficaci
need
improv
term
durat
protect
clinic
virolog
protect
even
though
commerci
bovin
vaccin
probabl
reduc
preval
infect
brsv
continu
circul
cattl
popul
commerci
vaccin
avail
hrsv
pathogen
major
import
infant
hrsv
inducedbronchiol
common
caus
infant
hospit
industri
countri
suspect
risk
factor
recurr
wheez
asthma
later
life
main
reason
lack
human
see
front
matter
human
bovin
respiratori
syncyti
virus
hrsv
brsv
two
close
relat
highli
infecti
worldwid
preval
virus
lead
caus
acut
lower
respiratori
tract
diseas
children
calv
respect
rsv
neg
strand
rna
viru
belong
pneumoviru
genu
within
paramyxovirida
famili
frequenc
serious
brsv
diseas
regard
princip
health
problem
calf
rear
worldwid
respons
larg
econom
loss
dairi
beef
farm
frequenc
brsv
infect
high
cattl
less
viru
may
respons
vaccin
dramat
failur
late
sixti
formalin
inactiv
hrsv
vaccin
fail
protect
subsequ
infect
also
induc
exacerb
diseas
children
vaccin
augment
diseas
also
describ
calv
commerci
brsv
vaccin
withdrawn
market
reason
obstacl
vaccin
exist
need
immun
immunolog
immatur
young
infant
presenc
matern
antibodi
strong
suppress
effect
outcom
vaccin
anim
human
experiment
model
rodent
develop
find
immun
correl
protect
versu
diseas
exacerb
help
concept
safe
rsv
vaccin
altogeth
studi
highlight
delic
tune
cytotox
antivir
cell
rsvspecif
antibodi
although
gener
protect
rsv
infect
may
deleteri
effect
instanc
poorli
neutral
antibodi
low
avid
protect
rsv
epitop
lead
enhanc
respiratori
syncyti
viru
diseas
rsvf
g
glycoprotein
situat
surfac
virion
target
neutral
antibodi
research
hrsv
subunit
vaccin
essenti
focus
two
protein
use
chimer
fg
glycoprotein
fulllength
f
protein
recombin
protein
contain
central
antigen
domain
hrsv
g
protein
fuse
ctermin
end
albuminbind
domain
streptococc
g
protein
howev
recombin
g
f
chimer
fg
often
found
caus
enhanc
lung
patholog
upon
rsv
challeng
associ
prime
cell
addit
risk
diseas
exacerb
vaccin
anoth
critic
issu
human
bovin
rsv
vaccin
variabl
viral
isol
circul
worldwid
effect
bovin
human
vaccin
protect
nucleoprotein
n
cover
viral
rna
genom
form
viral
nucleocapsid
conserv
rsv
protein
major
target
cellular
immun
respons
rsv
thu
contrari
f
g
antigen
n
base
vaccin
offer
possibl
tcellmedi
crossprotect
immun
circul
rsv
strategi
aim
use
n
vaccin
stimul
cell
immun
focus
liveattenu
viru
vector
dna
vaccin
vaccin
mice
recombin
vaccinia
viru
encod
hrsv
n
protein
induc
partial
protect
similarli
immun
young
calv
recombin
vaccinia
viru
express
brsv
n
protein
induc
nonneutr
antibodi
prime
brsvspecif
prolif
respons
product
result
reduct
viral
replic
upper
lower
respiratori
tract
dna
immun
two
administr
plasmid
encod
brsvf
n
protein
prime
strong
cellmedi
immun
calv
drastic
reduc
viral
replic
clinic
sign
pulmonari
lesion
highli
virul
challeng
recent
nucleocapsidbas
dna
primeprotein
boost
vaccin
shown
confer
protect
brsv
replic
lung
patholog
compar
dna
liveattenu
vector
vaccin
subunit
vaccin
safer
present
risk
replicationintegr
genet
modifi
materi
howev
subunit
vaccin
use
nucleoprotein
n
poorli
investig
part
recombin
n
difficult
produc
solubl
protein
set
origin
technolog
engin
circular
nanoparticl
compos
recombin
n
structur
solv
nanoparticl
name
n
sr
subnucleocapsid
ring
structur
intranas
vaccin
mice
hrsv
n
sr
nanoparticl
prime
nspecif
cell
significantli
reduc
titer
rsv
lung
mice
follow
hrsv
challeng
without
sign
diseas
exacerb
one
major
limit
mous
model
absenc
respiratori
diseas
respons
rsv
infect
therefor
object
present
studi
evalu
potenc
n
sr
vaccin
calv
natur
host
brsv
display
clinic
respiratori
symptom
lung
lesion
upon
infect
n
amino
acid
sequenc
highli
conserv
bovin
human
rsv
strain
amino
acid
ident
took
opportun
test
whether
n
sr
hrsv
strain
long
would
provid
crossprotect
immun
viral
challeng
brsv
strain
data
present
studi
show
vaccin
nanor
n
sr
partial
protect
respiratori
diseas
viru
replic
upon
brsv
challeng
without
sign
vaccinemedi
diseas
exacerb
pgexpct
code
residu
ctermin
fragment
phosphoprotein
name
pct
fuse
glutathionestransferas
petn
plasmid
contain
sequenc
hrsv
long
strain
describ
previous
randomprim
cdna
synthesi
done
use
superscriptii
gibco
invitrogen
life
scienc
franc
g
total
cytoplasm
rna
isol
bovin
turbin
cell
infect
strain
brsv
cdna
amplifi
pcr
high
fidel
pfuturbo
polymeras
stratagen
agil
technolog
franc
ng
follow
primer
amplifi
fulllength
cdna
code
brsv
n
protein
digest
subsequ
ncoi
xhoi
clone
vector
novagen
merck
chemic
product
germani
pct
code
amino
acid
residu
brsv
p
protein
digest
subsequ
bamhi
xhoi
insert
express
vector
pharmacia
franc
construct
verifi
sequenc
protein
e
coli
e
coli
novagen
merck
chemic
product
germani
cell
cotransform
pgexpct
petn
plasmid
code
either
brsv
hrsv
protein
recombin
protein
express
induc
iptg
protein
purifi
glutathionesepharos
affin
pharmacia
franc
hrsv
n
pct
complex
separ
glutathionesepharos
bead
biotinylatedthrombin
cleavag
tri
mm
ph
nacl
mm
thrombin
remov
thrombin
cleavag
captur
kit
accord
manufactur
instruct
novagen
merck
chemic
product
germani
protocol
allow
purif
recombin
hrsv
n
protein
via
capac
interact
ctermin
fragment
p
fuse
gst
name
gstpct
previous
describ
accord
procedur
n
protein
assembl
ringshap
structur
contain
rna
subsequ
name
n
sr
subnucleocapsid
ring
structur
two
hundr
fifti
milligram
hrsv
n
sr
produc
im
inject
n
sr
formul
montanid
tm
vg
seppic
air
liquid
franc
final
concentr
mgml
montanid
tm
isa
vg
blend
oil
ester
mannitol
sugar
oleic
fatti
acid
anhydromannitol
octadeceno
ether
specif
emulsifi
properti
due
sugar
polar
head
nonion
specif
fatti
acid
chain
surfact
system
oleic
acid
sugar
polar
part
use
veget
origin
experiment
small
scale
vaccin
emuls
perform
use
silverson
tubular
system
mixer
ratio
montanid
tm
vgaqueou
phase
g
g
antigen
phase
montanid
tm
vg
ad
first
beaker
head
silverson
place
oil
agit
rpm
appropri
amount
antigen
phase
temperatur
montanid
tm
vg
ad
progress
rotat
speed
increas
rpm
min
gentl
move
beaker
control
n
sr
denatur
emuls
montanid
tm
vg
ml
butanol
ad
ml
emuls
result
separ
aqueou
organ
phase
protein
present
aqueou
phase
dose
imag
negativestain
microscopi
philip
microscop
oper
acceler
voltag
kv
administr
n
sr
formul
vv
montanid
tm
im
vg
seppic
air
liquid
franc
final
concentr
mgml
montanid
tm
im
vg
readi
dilut
watersolubl
vaccin
adjuv
montanid
tm
im
associ
apolar
amphiphil
nanoparticl
combin
solubl
immunostimul
raw
materi
use
formul
monograph
differ
pharmacopeia
andor
alreadi
use
inject
human
adjuv
specif
select
intranas
trial
due
high
spreadabl
experiment
vaccin
formul
done
simpl
dilut
antigen
media
adjuv
gentl
magnet
steer
brsv
isol
isol
nasal
swab
calf
distress
respiratori
syndrom
viru
replic
five
passag
bovin
turbin
cell
american
type
cultur
collect
crl
amplifi
passag
newborn
calv
give
inoculum
passag
newborn
calv
perform
follow
calf
depriv
colostrum
matern
antibodi
inocul
intranas
intratrach
rout
pfu
calf
euthan
anesthesia
day
later
bronchoalveolar
lavag
bal
perform
lung
ml
mem
medium
supplement
enrofloxacin
gml
baytril
bayer
franc
fungizon
gml
invitrogen
life
scienc
franc
bal
snap
frozen
c
method
use
obtain
store
bal
second
third
passag
challeng
inoculum
present
studi
consist
bal
third
passag
free
follow
bovin
respiratori
pathogen
mannheimia
haemolytica
pasteurella
multocida
mycoplasma
bovi
bovin
viral
diarrhea
viru
bvdv
bovin
parainfluenza
type
bovin
adenoviru
bovin
coronaviru
bovin
herpesviru
titr
challeng
inoculum
pfuml
infect
inoculum
control
challeng
pfuml
test
h
experiment
infect
tabl
twentyfour
normandi
holstein
breed
male
calv
select
birth
rear
isol
unit
level
bio
safeti
inra
experiment
platform
infectiolog
nouzilli
franc
birth
euthanasia
alloc
specif
unit
accord
experiment
group
anim
hous
biocontain
facil
prescrib
guidelin
european
commun
council
anim
care
author
licenc
issu
direct
de
servic
accredit
number
calv
colostrum
depriv
day
birth
receiv
substitut
colostrum
cer
marloi
belgium
oral
rout
day
protect
enterit
pathogen
fed
commerci
milk
first
age
sander
ouest
sa
champagn
franc
antibiot
mgkg
cefquinom
cobactan
scherringplough
intervet
franc
administr
birth
day
absenc
matern
antibodi
brsv
confirm
igg
detect
indirect
brsv
elisa
lsi
lissieu
franc
blood
calv
day
birth
brsv
elisa
also
perform
week
inocul
rule
natur
brsv
infect
rear
absenc
bvdv
calv
assess
birth
one
week
challeng
neg
detect
bvdv
antigen
serelisa
bvdvbd
synbiot
lyon
franc
neg
rtpcr
calv
remain
healthi
period
challeng
end
experi
calv
found
seroneg
bovin
parainfluenza
type
calv
randomli
alloc
three
group
day
day
vaccin
consid
day
first
group
calv
vaccin
twice
week
interv
mg
n
sr
protein
montanid
tm
vg
adjuv
intramuscular
rout
ml
left
flank
second
group
calv
receiv
twice
week
interv
mg
n
sr
protein
montanid
tm
vg
adjuv
intramuscular
rout
ml
left
flank
mg
n
sr
protein
montanid
tm
im
vg
adjuv
intranas
rout
ml
per
nostril
use
nebuliz
devic
medic
use
wolf
tori
medic
utah
usa
dose
antigen
defin
accord
one
preliminari
experi
done
calf
test
safeti
immunogen
n
sr
adjuv
formul
shown
last
group
calv
untreat
serv
neg
control
two
vaccin
regimen
three
week
final
vaccin
calv
challeng
pfu
inoculum
intranas
nebul
ml
tracherin
ibr
vaccin
nebuliz
intratrach
rout
ml
intraflon
cathet
vycon
franc
two
calv
per
group
euthan
gener
anesthesia
overdos
mgkg
ketamin
follow
mgkg
pentobarbit
sodium
day
postchalleng
day
remain
euthan
day
postchalleng
day
calv
observ
clinic
sign
respiratori
tract
diseas
day
prior
infect
day
postinfect
clinic
assess
made
time
twice
day
veterinarian
calv
examin
bodi
temperatur
nasal
discharg
cough
decreas
appetit
gener
state
abnorm
breath
respiratori
rate
abnorm
lung
sound
clinic
score
done
calf
alreadi
describ
slight
modif
rectal
temperatur
respiratori
frequenc
evalu
separ
score
respiratori
rate
rrmin
rr
rr
rr
rr
score
normal
mild
sever
attribut
nasal
discharg
cough
decreas
appetit
gener
state
dyspnoea
abnorm
lung
sound
paramet
respect
fold
coeffici
subsequ
attribut
respiratori
rate
nasal
discharg
cough
decreas
appetit
gener
state
dyspnoea
abnorm
lung
sound
paramet
respect
follow
antigenspecif
antibodi
respons
nasal
swab
pb
tween
antiproteas
complet
mini
roch
appli
scienc
indianapoli
usa
blood
sampl
collect
day
monitor
viru
detect
challeng
nasal
swab
collect
daili
day
anim
ml
rltbuffer
qiagen
sa
franc
real
time
rtpcr
ml
pb
buffer
commerci
eia
assay
speed
respivb
bvt
la
seynesurm
franc
complet
necropsi
calv
perform
immedi
euthanasia
day
lymphat
node
prescapular
tracheobronchi
mediastin
dissect
process
subsequ
cell
assay
lung
macroscop
lesion
record
standard
lung
diagram
express
pneumon
consolid
cranial
lobe
photograph
taken
bal
perform
ml
dmem
supplement
antibiot
cell
numer
bal
cell
cytocentrifug
cytospin
shandon
thermo
scientif
franc
superfrost
plu
slide
milan
franc
stain
cell
fix
cytochex
streck
ne
usa
flow
cytometri
analysi
leftov
bal
cell
lyse
rltbuffer
rneasi
mini
qiagen
sa
franc
rna
extract
microscop
analysi
perform
tissu
sampl
right
cranial
lobe
lung
fix
formaldehyd
embed
paraffin
section
deparaffin
counterstain
hematoxylineosinsaffran
analyz
photograph
examin
bacteri
infect
perform
tissu
sampl
gram
stain
sampl
cranial
lobe
lung
also
collect
rnalat
qiagen
sa
franc
subsequ
brsv
quantif
real
time
rtpcr
viru
shed
nasal
swab
quantit
determin
real
time
rtpcr
assay
accord
boxu
et
al
except
quantit
analysi
brsv
rna
perform
rel
bovin
dehydrogenas
gapdh
express
housekeep
gene
rtpcr
use
quantif
brsv
bal
lung
tissu
paraffinembed
lung
tissu
section
deparaffin
rehydr
tri
ph
cacl
permeabil
saponin
sigmaaldrich
franc
brsv
antigen
detect
use
moab
anti
rsvf
clone
abd
serotec
germani
dilut
tri
ph
cacl
saponin
irrelev
isotypematch
mous
ab
use
control
nonspecif
stain
bind
primari
ab
reveal
ad
hrpconjug
antimous
igg
follow
insolubl
peroxydas
substrat
diaminobenzidin
sigmafast
tm
sigmaaldrich
franc
tissu
section
counterstain
hematoxylin
one
million
bal
cell
incub
min
rpmi
contain
hors
serum
rpmih
ice
bal
cell
stain
min
ice
mous
moab
antibovin
clone
vmrd
wa
usa
igm
clone
vmrd
wa
usa
clone
vmrd
wa
usa
match
isotyp
control
mous
antibodi
dilut
rpmih
bal
cell
wash
incub
anoth
min
antiisotyp
antibodi
conjug
fluorochrom
fitc
pe
antiigm
invitrogen
life
scienc
franc
cell
fix
cellfix
bd
bioscienc
franc
sampl
analyz
facscalibur
bd
bioscienc
franc
collect
data
least
lymphocyt
gate
accord
forward
side
scatter
featur
lymph
node
mechan
disrupt
cell
dissoci
steril
medium
plu
fetal
calf
serum
fc
c
recov
cell
filter
steril
cell
strainer
bd
bioscienc
franc
wash
twice
medium
plu
fc
pbmc
lymph
node
cell
final
suspend
xvivo
medium
biowhittak
lonza
switzerland
supplement
fc
mm
lglutamin
uml
penicillin
mgml
streptomycin
cultiv
vitro
cell
prolifer
detect
assay
prolifer
assay
carri
flatbottom
plate
isol
lymph
node
cell
seed
triplic
cell
per
well
without
n
sr
gml
final
concentr
plate
incub
c
co
h
puls
overnight
ci
h
thymidin
per
well
cell
collect
filter
mat
use
cell
harvest
filterm
perkinelm
franc
radioact
measur
liquid
scintil
luminesc
counter
microbeta
trilux
wallac
inc
gaithersburg
md
usa
result
express
stimul
index
cpm
stimul
cell
cpm
unstimul
control
cell
lymph
node
cell
plate
plate
falcon
triplic
cell
per
well
incub
c
co
without
n
sr
gml
final
concentr
supernat
harvest
h
content
test
use
specif
elisa
test
bovigam
biocor
melbourn
australia
accord
manufactur
instruct
result
express
stimul
index
od
nm
n
sr
stimul
cell
od
unstimul
control
cell
individu
sera
nasal
secret
assay
nspecif
antibodi
total
ig
iga
elisa
microtit
plate
immulon
thermo
labsystem
franc
coat
overnight
c
n
antigen
ng
per
well
l
carbonatebicarbon
buffer
ph
plate
wash
five
time
pb
tween
step
assay
coat
remain
protein
bind
site
satur
hors
serum
pb
tween
pbsth
h
c
sampl
serial
dilut
threefold
pbsth
start
sera
nasal
secret
incub
h
c
antigenbound
ab
detect
use
hrpconjug
antibovin
ig
h
l
hrpconjug
sheep
antibovin
rabbit
antibovin
iga
abd
serotec
germani
dilut
incub
h
c
follow
requir
incub
goat
antirabbit
ig
hrpconjug
tmb
substrat
kirkegaard
perri
laboratori
inc
md
usa
ad
reaction
stop
min
phosphor
acid
absorb
measur
nm
elisa
plate
reader
mrx
revel
dynex
technolog
germani
result
express
endpoint
antibodi
titer
calcul
regress
analysi
plot
dilut
versu
regress
curv
b
cx
ax
use
origin
softwar
endpoint
titer
calcul
highest
dilut
give
twice
absorb
neg
control
sampl
altern
plate
coat
lysat
brsvinfect
mockinfect
turbin
cell
pb
lysat
obtain
treat
brsvinfect
mockinfect
turbin
cell
noctyl
glucosid
sigmaaldrich
franc
mm
edta
mm
ph
tri
salin
buffer
serum
sampl
dilut
incub
altern
row
brsvinfect
mockinfect
turbin
lysat
elisa
perform
describ
measur
antibrsvspecif
bind
background
antibodi
bind
control
lysat
substract
bind
brsvinfect
cell
lysat
data
express
arithmet
mean
standard
error
mean
sem
statist
analysi
immun
paramet
perform
use
nonparametr
mannwhitney
utest
http
level
signific
indic
graph
star
p
p
p
peak
clinic
sign
viral
load
valu
compar
oneway
analysi
varianc
logarithm
transform
appli
fulfil
condit
varianc
homogen
normal
necessari
threefactor
splitplot
anova
test
use
calcul
effect
factor
day
vaccin
group
signific
result
bonferroni
test
among
contrast
use
compar
two
condit
day
postchalleng
nanor
obtain
n
hrsv
long
strain
formul
montanid
tm
adjuv
test
immunogen
previous
shown
solubl
rnanucleoprotein
complex
form
nanor
n
sr
purifi
bacteria
express
recombin
n
ctermin
region
residu
p
protein
pct
hrsv
long
strain
protocol
use
order
purifi
brsv
n
protein
brsv
n
protein
coexpress
pct
either
hrsv
brsv
origin
shown
fig
brsv
n
protein
strain
recov
unsolubl
fraction
bacteri
lysat
attempt
purifi
coexpress
gstpct
unsuccess
either
use
pct
brsv
hrsv
origin
hand
hrsv
n
protein
solubl
effici
purifi
brsv
pct
fuse
gst
fig
n
protein
human
strain
long
bovin
strain
highli
conserv
sinc
share
sequenc
amino
acid
ident
amino
acid
sequenc
similar
fig
thu
use
n
sr
nanor
deriv
hrsv
long
strain
vaccin
candid
brsv
infect
control
n
sr
degrad
emulsif
montanid
tm
vg
montanid
tm
vg
protein
present
two
formul
analyz
sdspage
nativ
gel
electrophoresi
electron
microscopi
describ
previous
case
n
protein
recov
sr
data
shown
intramuscular
inject
classic
way
vaccin
bovin
previou
data
mice
show
nasal
vaccin
nanor
n
sr
effici
immun
rout
prevent
hrsv
replic
lung
thu
decid
administ
n
sr
vaccin
via
intramuscular
intranas
rout
time
group
n
sr
im
test
benefit
nasal
vaccin
comparison
group
calv
receiv
vaccin
intramuscular
inject
group
n
sr
im
calv
vaccin
twice
week
interv
third
group
calv
left
untreat
group
vaccin
advers
clinic
reaction
observ
first
second
immun
monitor
immunogen
vaccin
regimen
nspecif
antibodi
investig
serum
sampl
nasal
secret
fig
calv
vaccin
n
sr
either
im
im
display
antin
ab
serum
nasal
secret
detect
first
immun
increas
booster
immun
fig
b
antin
ab
titer
differ
two
vaccin
group
nasal
antin
ab
respons
isotyp
fig
lower
antin
iga
titer
aris
mostli
booster
immun
fig
nasal
antin
ab
titer
higher
group
n
sr
im
compar
n
sr
im
p
ig
titer
p
iga
titer
day
nonvaccin
control
calv
signific
antin
ab
titer
blood
nasal
secret
viral
challeng
fig
b
p
day
day
ig
titer
vaccin
group
antibodi
elicit
upon
n
sr
vaccin
also
abl
recogn
nativ
viral
n
shown
specif
bind
brsvinfect
turbin
cell
antigen
od
day
group
vaccin
n
sr
im
n
sr
im
respect
p
vaccin
nonvaccin
calv
challeng
calv
show
mild
clinic
sign
upper
respiratori
tract
infect
essenti
character
slight
mucou
nasal
discharg
except
one
calf
group
n
sr
im
remain
healthi
cough
observ
two
nonvaccin
calv
day
moder
hyperthermia
observ
calv
statist
differ
group
data
shown
respiratori
sign
consist
moder
high
increas
respiratori
rate
mild
dyspnoea
increas
lung
sound
dyspnoea
also
associ
wheez
crackl
calv
among
calv
nonvaccin
control
group
one
calf
slightli
affect
calv
moder
ill
one
calf
develop
mark
dyspnoea
abnorm
breath
discord
surround
lung
sound
cranial
lobe
wheez
crackl
six
calv
group
n
sr
im
one
calf
show
clinic
sign
calv
develop
mild
respiratori
symptom
calv
develop
moder
dyspnoea
final
calv
group
n
sr
im
develop
mild
respiratori
sign
show
moder
dyspnoea
mean
clinic
score
shown
fig
statist
analys
threefactor
splitplot
anova
test
indic
group
time
effect
nonvaccin
group
group
n
sr
im
n
sr
im
differ
found
two
vaccin
group
n
sr
im
n
sr
im
signific
reduct
mean
clinic
score
bonferroni
test
among
contrast
p
found
group
n
sr
im
day
group
n
sr
im
day
postinfect
compar
nonvaccin
group
fig
onset
peak
durat
clinic
score
calcul
group
tabl
show
delay
onset
peak
shorter
durat
clinic
symptom
two
vaccin
group
thu
calv
vaccin
n
sr
either
im
im
fig
clinic
score
follow
brsv
challeng
respiratori
rhythm
anorexia
presenc
nasal
discharg
lung
sound
cough
demeanour
record
daili
challeng
clinic
score
calcul
data
repres
mean
sem
n
group
day
challeng
day
challeng
star
indic
signific
differ
two
vaccin
group
n
sr
im
im
nonvaccin
one
partli
protect
respiratori
diseas
caus
viru
challeng
two
calv
group
euthan
day
challeng
lung
examin
extent
macroscop
lesion
record
anim
gross
lesion
restrict
cranial
lobe
except
one
nonvaccin
calf
show
lesion
also
middl
accessori
lobe
patchi
area
atelectas
collaps
deep
red
rubberi
textur
extens
lung
lesion
calv
detail
tabl
right
left
cranial
lobe
respect
summar
extens
consolid
lesion
vari
fig
right
cranial
lobe
unvaccin
calv
estim
vaccin
calv
fig
right
cranial
lobe
macroscop
lesion
found
calv
euthan
day
postchalleng
histolog
examin
lung
tissu
section
sampl
right
cranial
lobe
taken
site
macroscop
lesion
reveal
typic
bronchointerstiti
pneumonia
fig
e
character
necrot
bronchiol
format
bronchiolar
epitheli
syncitia
prolif
alveol
calv
nonvaccin
group
contrast
lung
tissu
section
vaccin
calv
n
sr
im
n
sr
im
show
limit
cellular
infiltr
peribronchiolar
bronchiolar
area
minim
densif
alveolar
area
shown
one
n
sr
im
calv
fig
besid
bronchiolar
lumina
clear
cellular
debri
fig
presenc
brsvinfect
cell
reveal
immunostain
lung
tissu
section
brsvspecif
stain
found
epitheli
cell
bronchiol
either
vaccin
nonvaccin
calv
fig
h
brown
stain
replic
brsv
respiratori
tract
infect
calv
investig
real
time
rtpcr
bal
cell
b
lung
piec
sampl
right
cranial
lobe
border
red
atelectat
collaps
pulmonari
area
healthi
tissu
fix
formalin
embed
paraffin
histolog
examin
section
counterstain
hematoxylineosinsaffran
show
area
bronchointerstiti
pneumonia
prolif
alveol
nonvaccin
calv
mark
infiltr
inflammatori
cell
observ
alveolar
peribronchiolar
bronchiolar
area
c
associ
necrot
bronchiol
e
bronchiolar
lumen
contain
slough
necrot
epitheli
cell
sometim
multinucl
syncyti
cell
close
associ
bronchiolar
epithelium
inflammatori
cell
infiltr
bronchiolar
epithelium
similar
section
vaccin
calv
show
alveolar
function
area
minim
thicken
alveolar
septa
bronchiolar
lumen
clear
cellular
debri
f
lung
tissu
section
stain
brsv
antigen
antif
monoclon
antibodi
brown
stain
counterstain
hematoxylin
pale
blue
stain
control
immunohistochem
reaction
isotypematch
irrelev
mous
igg
neg
data
shown
immunohistochem
stain
brsvf
reveal
virusinfect
bronchiolar
epitheli
cell
g
h
viral
antigen
among
necrot
cell
slough
bronchiol
lumen
g
interpret
refer
color
figur
legend
reader
refer
web
version
articl
lung
sampl
right
cranial
lobe
day
postinfect
viral
rna
detect
bal
cell
lung
tissu
two
euthan
calv
group
signific
differ
group
fig
data
agreement
find
brsvinfect
cell
lung
tissu
section
immunostain
viru
could
detect
day
postinfect
bal
lung
calv
kinet
amount
viru
shed
monitor
nasal
secret
daili
basi
postchalleng
brsv
rna
detect
nasal
secret
infect
calv
fig
c
brsv
rna
detect
viral
load
follow
challeng
viral
load
examin
perform
quantit
real
time
rtpcr
total
rna
extract
bal
cell
lung
piec
collect
two
calv
per
group
euthan
day
challeng
nasal
swab
sampl
daili
day
challeng
day
b
c
viral
load
express
log
brsv
copi
per
gapdh
cdna
mean
sem
n
star
indic
signific
differ
two
vaccin
group
n
sr
im
im
nonvaccin
one
daili
percentag
posit
calv
per
group
shown
c
peak
viru
shed
day
postchalleng
copi
gapdh
group
vaccin
n
sr
im
n
sr
im
respect
signific
differ
found
two
vaccin
group
howev
statist
analys
threefactor
splitplot
anova
test
indic
group
time
differ
two
vaccin
group
nonvaccin
group
lower
amount
viral
rna
found
group
n
sr
im
day
p
p
group
n
sr
im
day
p
fig
importantli
durat
viral
excret
nasal
swab
reduc
vaccin
group
brsv
detect
swab
day
postinfect
nonvaccin
calv
versu
day
group
n
sr
im
day
group
n
sr
im
fig
addit
detect
brsv
protein
nasal
secret
eia
assay
five
calv
group
day
postinfect
show
less
calv
found
posit
daili
fig
cell
subset
recruit
bal
follow
brsv
infect
two
calv
per
group
euthan
day
brsv
challeng
calv
euthan
day
challeng
lung
dissect
thorac
cage
lavag
ml
medium
cell
present
bal
collect
cytocentrifug
cellular
composit
bal
establish
color
numer
macrophag
lymphocyt
neutrophil
eosinophil
bal
cell
label
antibodi
analyz
flow
cytometri
determin
lymphocyt
subset
recruit
lung
upon
infect
b
event
acquir
gate
lymphocyt
accord
fscssc
criteria
least
event
gate
data
mean
sem
n
day
n
day
basi
two
vaccin
group
compar
nonvaccin
group
data
shown
respiratori
infect
usual
accompani
influx
lymphocyt
granulocyt
lung
bal
cell
collect
calv
euthan
day
n
n
challeng
percentag
macrophag
lymphocyt
neutrophil
eosinophil
determin
stain
six
day
infect
observ
neutrophil
bal
whether
calv
vaccin
n
fig
black
bar
twenti
day
postchalleng
percentag
neutrophil
bal
rang
without
signific
differ
three
group
vaccin
n
sr
im
n
sr
im
eosinophil
found
bal
day
postchalleng
fig
get
insight
pattern
cell
respons
lung
upon
challeng
lymphocyt
bal
monitor
flow
cytometri
analysi
fig
lymphocyt
gate
accord
low
fscssc
featur
memoryactiv
lymphocyt
subsequ
gate
basi
express
proport
cell
within
gate
lymphocyt
determin
nonvaccin
calv
experienc
primari
brsv
infect
effector
lymphocyt
found
rapidli
abundantli
counterpart
airway
fig
day
pattern
cell
subset
day
postchalleng
mem
oryeffector
cell
observ
n
sr
im
vaccin
calv
wherea
calv
group
vaccin
n
sr
im
tend
memoryeffector
cell
airway
day
postchalleng
cell
found
proport
among
bal
cell
without
signific
differ
group
primari
brsv
infect
calv
n
known
target
cellmedi
immun
thu
test
whether
n
sr
vaccin
prime
memori
cell
respons
could
reveal
postchalleng
leukocyt
isol
lymph
node
day
postbrsv
challeng
restimul
vitro
n
sr
nspecif
cellular
respons
measur
prolifer
index
base
tritiat
thymidin
incorpor
fig
get
insight
function
lymphocyt
elicit
upon
n
sr
immun
brsv
challeng
capac
make
assess
elisa
lymph
node
cell
cultur
supernat
fig
nspecif
cell
respons
prime
prescapular
lymph
node
drain
site
im
vaccin
n
sr
n
sr
vaccin
calv
display
nspecif
prolif
respons
stimul
index
n
sr
im
n
sr
im
respect
versu
nonvaccin
calv
p
accordingli
capac
cell
isol
prescapular
ln
make
significantli
higher
vaccin
calv
nonvaccin
one
p
vaccin
n
sr
im
cell
isol
lymph
node
drain
upper
airway
tracheobronchi
ln
lung
mediastin
ln
prolifer
respons
n
sr
mean
prolifer
index
two
vaccin
group
differ
nonvaccin
group
suggest
cell
prime
mainli
due
brsv
infect
howev
cell
memori
respons
monitor
product
tracheobronchi
ln
vaccin
calv
higher
respons
nonvaccin
one
p
vaccin
n
sr
im
strongest
product
record
mediastin
ln
tend
higher
cell
isol
vaccin
calv
si
vaccin
n
sr
im
n
sr
im
respect
p
vaccin
n
sr
im
p
vaccin
n
sr
im
thu
respons
lymph
node
drain
airway
suggest
memori
cell
prime
n
sr
vaccin
boost
upon
brsv
challeng
rsv
vaccin
yet
licens
human
use
inactiv
attenu
vaccin
commerci
bovin
limit
efficaci
short
durat
protect
immun
difficulti
rsv
vaccin
develop
includ
lack
relev
anim
model
human
need
immun
immunolog
immatur
young
infant
calv
matern
rsv
antibodi
impact
rsv
variabl
vaccin
risk
vaccineassoci
diseas
enhanc
first
publish
effici
safe
vaccin
strategi
rsv
use
nucleocapsid
protein
alon
vaccin
antigen
form
solubl
nanoparticl
refer
n
sr
previou
studi
done
mice
demonstr
n
sr
highli
immunogen
deliv
via
nasal
rout
immun
respons
prime
upon
vaccin
protect
hrsv
challeng
present
studi
investig
potenc
n
sr
vaccin
calv
natur
host
brsv
display
clinic
respiratori
symptom
lung
lesion
upon
infect
find
indic
calv
vaccin
n
sr
partial
protect
respiratori
diseas
caus
viru
challeng
significantli
lower
clinic
score
observ
two
three
day
vaccin
calv
compar
nonvaccin
calv
durat
clinic
sign
reduc
vaccin
calv
precis
site
virusinduc
lesion
cranial
lobe
lung
vaccin
n
sr
reduc
extent
local
inflammatori
consolid
vaccin
n
sr
reduc
durat
viral
shed
frequenc
virussecret
calv
daili
basi
prevent
viral
shed
nasal
secret
viral
replic
lung
differ
two
vaccin
regimen
im
im
capac
reduc
clinic
score
viral
load
importantli
degre
protect
confer
vaccin
n
sr
associ
marker
diseas
exacerb
like
eosinophilia
report
vaccin
calv
fibrsv
livebrsv
inde
eosinophil
neutrophil
found
bronchoalveolar
lavag
calv
autopsi
week
challeng
sever
point
discuss
could
explain
partial
protect
calv
vaccin
n
sr
whatev
protocol
use
clear
respiratori
symptom
lung
lesion
induc
upon
brsv
challeng
sever
frequent
publish
brsv
challeng
model
difficult
reproduc
sever
clinic
sign
lesion
observ
upon
natur
infect
calv
normal
bred
farm
isol
unit
like
present
studi
bacteri
viru
coinfect
complic
classic
brsv
diseas
bovin
parainfluenza
viru
widespread
cattl
reduc
pulmonari
defenc
thu
may
enhanc
sever
brsv
pathogen
virus
brsv
import
predispos
factor
develop
bacteri
bronchopneumonia
cattl
addit
intrins
host
paramet
seem
control
sever
diseas
sinc
sever
patholog
associ
dysfunct
host
respons
studi
use
brsv
inoculum
previous
shown
success
reproduc
sever
respiratori
sign
intranas
intratrach
inject
primholstein
calv
g
meyer
unpublish
result
inoculum
contain
brsv
passag
cell
cultur
cycl
amplif
newborn
calv
condit
also
shown
other
induc
sever
respiratori
diseas
calv
comparison
previou
success
experi
failur
reproduc
respiratori
distress
syndrom
studi
could
relat
host
intrins
paramet
inde
anoth
studi
use
inoculum
cross
primholsteinnormandi
calv
origin
also
fail
reproduc
respiratori
distress
nucleoprotein
subunit
n
sr
use
studi
hrsv
origin
gene
encod
nucleoprotein
shown
one
conserv
brsv
hrsv
averag
amino
acid
ident
nucleoprotein
brsv
recogn
bovin
cell
precis
ctl
epitop
defin
yet
human
restrict
epitop
map
nucleoprotein
interestingli
amino
acid
sequenc
fulli
conserv
among
variou
hrsv
field
isol
brsv
strain
mechan
ctl
crossreact
recent
investig
wellcharacter
ctl
epitop
hiv
show
biochem
similar
amino
acid
substitut
drastic
affect
recognit
tcr
level
crossprotect
hrsv
brsv
demonstr
cotton
rat
model
brsv
test
possibl
jennerian
vaccin
hrsv
among
viral
antigen
may
cross
protect
brsv
hrsv
brsvf
amino
acid
ident
hrsvf
deliv
dna
vaccin
shown
protect
mice
hrsv
challeng
present
studi
bring
new
data
support
hypothesi
common
b
epitop
brsv
hrsv
nucleoprotein
inde
studi
primari
brsv
infect
result
antibodi
cellular
immun
could
reveal
n
sr
coat
elisa
assay
follow
vitro
boost
n
sr
respect
convers
serum
ab
n
sr
vaccin
calv
react
brsvinfect
cell
lysat
indic
recombin
n
hrsv
origin
assembl
nanor
nucleocapsid
protein
n
brsv
strain
display
least
common
epitop
vaccin
n
sr
hrsv
protein
sequenc
provid
signific
crossprotect
brsv
challeng
calv
final
sever
paramet
dose
vaccin
type
adjuv
rout
administr
may
influenc
degre
protect
oil
base
adjuv
n
sr
vaccin
montanid
tm
rang
present
sever
veterinari
vaccin
use
field
erad
viral
diseas
eg
foot
mouth
diseas
mani
countri
decad
present
studi
aim
induc
strong
cellular
respons
therefor
select
dedic
miner
oil
base
adjuv
intramuscular
vaccin
isa
vg
intranas
vaccin
select
one
adjuv
montanid
tm
im
technolog
im
vg
physic
properti
flowabl
viscos
permit
easi
deliveri
anim
nostril
intramuscular
rout
classic
way
inject
inactiv
vaccin
true
live
viru
intranas
vaccin
livebrsv
modifiedlivebrsv
vaccin
shown
efficaci
reduc
viral
shed
intramuscular
administr
young
calv
moreov
singl
intranas
vaccin
previous
shown
prime
calv
face
matern
antibodi
commerci
avail
modifiedlivebrsv
vaccin
formul
licens
parenter
use
shown
induc
partial
protect
administ
intranas
recent
singl
intranas
dose
bival
modifiedl
vaccin
shown
reduc
nasal
shed
brsv
challeng
day
postvaccin
despit
low
brsv
neutral
antibodi
titer
detect
vaccin
thu
chosen
two
vaccin
regimen
use
present
studi
base
hypothesi
administr
n
sr
via
nasal
rout
would
strengthen
level
protect
confer
intramuscular
vaccin
howev
differ
clinic
viral
protect
observ
calv
vaccin
intramuscularli
versu
intramuscularli
plu
intranas
could
explain
weak
respons
intranas
vaccin
mask
immun
respons
induc
intranas
vaccin
obtain
intramuscular
vaccin
unfortun
due
restrict
number
brsv
seroneg
calv
possibl
supplementari
group
calv
vaccin
intranas
rout
intramuscular
administr
n
sr
power
stimul
mucos
system
ab
respons
cellular
immun
intranas
administr
n
sr
given
im
immun
increas
immun
respons
level
upper
respiratori
tract
memori
cell
produc
tracheobronchi
lymph
node
antigenspecif
iga
nasal
secret
express
consid
reliabl
marker
monitor
activ
cell
bovin
context
primari
infect
brsv
cell
predomin
subset
recruit
airway
prior
vaccin
inactiv
liveattenu
viru
modifi
pattern
cell
respons
report
previous
preferenti
prime
respons
follow
challeng
mice
vaccin
intranas
n
sr
thu
possibl
intranas
deliveri
n
sr
respons
earli
presenc
cell
bovin
airway
postchalleng
im
vaccin
calv
howev
nasal
vaccin
might
effici
enough
prime
protect
local
antivir
immun
could
relat
type
adjuv
use
deliveri
devicerout
antigen
addit
studi
necessari
improv
intranas
vaccin
n
sr
test
sever
dose
antigen
associ
adjuv
use
intranas
deliveri
compar
result
obtain
intramuscular
vaccin
immun
correl
viral
clinic
protect
afford
n
sr
vaccin
shown
previou
studi
mice
antibodi
rais
n
neutral
thu
unlik
involv
antivir
protect
cellular
immun
mediat
virusspecif
cell
requir
clear
brsv
lung
infect
calv
primari
infect
n
one
main
target
cell
respons
brsv
present
studi
shown
n
sr
vaccin
prime
antigenspecif
cell
memori
respons
character
capac
prolifer
secret
studi
impli
n
sr
vaccin
mous
lamb
anim
model
shown
nspecif
memori
cell
prime
riffault
unpublish
result
recent
vaccin
regimen
use
nucleoprotein
dna
primeprotein
boost
protocol
shown
superior
dna
protein
vaccin
alon
prime
antigenspecif
memori
cell
protect
brsv
replic
reduc
lung
patholog
howev
dna
vaccin
author
human
use
n
protein
alon
vaccin
newborn
children
could
interest
altern
approach
moreov
n
sr
produc
larg
amount
bacteria
nanor
structur
stabl
either
c
c
unpublish
observ
make
product
storag
cheap
easi
set
right
condit
crossprotect
cellular
immun
conserv
antigen
grow
challeng
vaccinolog
field
nowaday
eg
univers
influenza
vaccin
nucleoprotein
subunit
approach
describ
present
studi
effici
induc
crossprotect
immun
rsv
interestingli
n
sr
structur
potent
stimul
antibodi
respons
system
mucos
level
recent
obtain
xray
structur
n
sr
abl
map
expos
site
nanor
antigen
motif
graft
next
goal
improv
degre
protect
use
rsv
nucleocapsid
nanoparticl
graft
peptid
epitop
brsv
fusion
f
glyco
g
protein
order
trigger
neutral
antibodi
respons
addit
antin
cellular
respons
